- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02494986
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies
March 26, 2024 updated by: Janssen Sciences Ireland UC
An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies
The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an open-label (all people know the identity of the intervention), multicenter (more than one hospital or clinical site work on a study), roll-over study to provide continued access to RPV for human immunodeficiency virus type 1 (HIV-1) infected participants.
All enrolled participants will continue to receive RPV in combination with an investigator-selected background regimen consisting of other antiretrovirals (ARVs).
Participants will continue to receive RPV in this study until one of the following criteria is met (whichever comes first) as determined in the study protocol: they meet at least one of the withdrawal criteria, or the participant has been treated in this roll-over study for 4 years (48 months) or older than 12 years of age and can continue RPV treatment outside of this roll-over study by switching to locally available RPV (if commercially available and reimbursed, or accessible through another source [example: access program or government program]) or other locally available RPV-based regimens.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Porto, Portugal
-
-
-
-
-
Bloemfontein, South Africa
-
Dundee, South Africa
-
-
-
-
-
Esplugues De Llobregat, Spain
-
-
-
-
-
Bangkok, Thailand
-
Nonthaburi, Thailand
-
-
-
-
-
Entebbe, Uganda
-
Kampala, Uganda
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants (or their legally acceptable representative) must sign an Informed Consent Form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Assent is also required of children capable of understanding the nature of the study (typically 7 years of age and older)
- Participants must be human immunodeficiency virus type 1 (HIV-1) infected and must have previously been treated with rilpivirine (RPV) 25 mg qd (or weight-adjusted dose) in a clinical development pediatric study and completed the protocol-defined treatment period
- Participants must benefit from treatment with RPV, according to the efficacy and safety criteria as set out in the protocol of the pediatric study with RPV the participant was participating in prior to this rollover study, and must be expected to continue to benefit from this treatment in the opinion of the investigator
- Participants must be able and willing to comply with the current protocol requirements
- Participants' general medical condition, in the opinion of the investigator, does not interfere with participation in this study
Exclusion Criteria:
- Participants using disallowed concomitant treatment
- Pregnant participants
- Female participants of childbearing potential and non-vasectomized heterosexually active male participants not willing to continue practicing birth control methods during the study and for greater than or equal to (≥)1 month after the end of the study (or after last intake of RPV)
- Participants who were withdrawn from a pediatric study with RPV that they were participating in prior to this rollover study, based on any of the mandatory withdrawal criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rilpivirine
Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other antiretrovirals (ARVs).
|
Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events (AEs) related to rilpivirine (RPV)
Time Frame: Up to 32 Days from the last dose administered (Approximately 16 years)
|
Evaluation of long term safety of the treatment with RPV with a background regimen.
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
Up to 32 Days from the last dose administered (Approximately 16 years)
|
Number of Participants with AEs Leading to Discontinuation
Time Frame: Up to 32 Days from the last dose administered (Approximately 16 years)
|
Number of participants with AEs leading to discontinuation will be reported.
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
Up to 32 Days from the last dose administered (Approximately 16 years)
|
Number of Participants with Serious Adverse Events (SAEs)
Time Frame: Up to 32 Days from the last dose administered (Approximately 16 years)
|
Number of participants with SAEs will be reported.
An SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
|
Up to 32 Days from the last dose administered (Approximately 16 years)
|
Number of Participants with Pregnancies
Time Frame: Up to 32 Days from the last dose of administered (Approximately 16 years)
|
Number of participants with pregnancies will be reported.
|
Up to 32 Days from the last dose of administered (Approximately 16 years)
|
Number or Participants with Grade 3/4 Rash Regardless of Causality
Time Frame: Up to 32 Days from the last dose administered (Approximately 16 years)
|
Number of participants with grade 3/4 rash regardless of causality will be reported.
|
Up to 32 Days from the last dose administered (Approximately 16 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Janssen R&D Ireland Clinical Trials, Janssen R&D Ireland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 6, 2015
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2031
Study Registration Dates
First Submitted
July 8, 2015
First Submitted That Met QC Criteria
July 8, 2015
First Posted (Estimated)
July 13, 2015
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Rilpivirine
Other Study ID Numbers
- CR107451
- TMC278IFD3004 (Other Identifier: Janssen R&D Ireland)
- 2014-002471-28 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus Type 1
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
Janssen Sciences Ireland UCCompletedImmunodeficiency Virus Type 1, HumanUnited States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
-
Bristol-Myers SquibbCompletedHuman Immunodeficiency Virus Type 1 (HIV-1)United States
-
Bristol-Myers SquibbCompletedHIV Infections | Human Immunodeficiency Virus Type 1 (HIV-1)United States, Netherlands
-
Tibotec Pharmaceuticals, IrelandCompletedHIV Infections | HIV-1 | Human Immunodeficiency Virus Type 1United States, Australia, France, United Kingdom, Taiwan, Spain, Argentina, Portugal, Romania, South Africa, Canada, Denmark, Sweden, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Mexico
-
ViiV HealthcareJanssen Research and DevelopmentCompletedHuman Immunodeficiency Virus Type 1 (HIV-1)Germany, Spain, United States, Italy, Canada, Argentina, Sweden
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompletedHuman Immunodeficiency Virus Type 1 (HIV-1)United States, Spain, Canada, United Kingdom, South Africa, Japan
-
Janssen PharmaceuticaWithdrawnHuman Immunodeficiency Virus Type 1 (HIV-1) Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
Clinical Trials on Rilpivirine
-
Janssen Sciences Ireland UCCompleted
-
Janssen Infectious Diseases BVBACompletedHuman Immunodeficiency Virus Type 1Belgium
-
ViiV HealthcareJanssen Research & Development, LLCRecruitingHIV InfectionsUnited States
-
ViiV HealthcareJanssen Research and DevelopmentActive, not recruitingHIV InfectionsUnited States, Germany, Spain, France, Canada, Korea, Republic of, Italy, South Africa, Australia, Russian Federation, Mexico, Sweden, Argentina
-
ViiV HealthcareJanssen, LPCompletedHIV InfectionsUnited States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
-
ViiV HealthcareJanssen, LPCompleted
-
University College, LondonLondon School of Hygiene and Tropical Medicine; MRC/UVRI and LSHTM Uganda Research... and other collaboratorsRecruitingHIV Infections | Hiv | HIV-1-infection | Paediatric Human Immunodeficiency Virus InfectionUganda, Zimbabwe, South Africa, Kenya
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompleted
-
Chiang Mai UniversityUnknownHIV-1-infection | Neurocognitive DysfunctionThailand
-
Tibotec Pharmaceuticals, IrelandCompleted